RxDoctor Payments DataLook up a doctor →

Albert Hicks, MD

Advanced Heart Failure and Transplant Cardiology · Temple, TXNPI 1386808012

Payments from drug & device makers

$656,420in general payments, 2019–2025

Across 716 payments — averaging $916.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$145K
  • Alnylam Pharmaceuticals Inc.$120K
  • Bridgebio Pharma, Inc.$76K
  • Abbott$74K
  • Cvrx, Inc.$73K
  • Lilly USA, LLC$65K
  • plus $104K from 14 others

What the payments were for

  • Consulting fees$131,02821%
  • Speaking & faculty fees$397,82365%
  • Travel & lodging$57,5639%
  • Food & beverage$26,9534%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$656,420 in reported general payments places this provider in the 90th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.

See all advanced heart failure and transplant cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$113,523
Medicare patients
152
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan68$88,321
JardianceEmpagliflozin80$83,554
EliquisApixaban18$16,426
XareltoRivaroxaban13$10,226
Metoprolol Succinate90$1,542
Eplerenone17$832
Carvedilol44$656
Spironolactone84$625
Atorvastatin Calcium17$561
Amiodarone Hcl11$332
Hydralazine Hcl17$331
Losartan Potassium23$322
Torsemide11$273
ClopidogrelClopidogrel Bisulfate16$215
Furosemide39$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$40,284$88,32168 claims
Boehringer IngelheimJardiance$144,932$83,55480 claims
PfizerEliquis$20,945$16,42618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.

Other advanced heart failure and transplant cardiology in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →